@phdthesis{Grotemeyer2019, author = {Grotemeyer, Alexander}, title = {Characterisation and application of new optogenetic tools in \(Drosophila\) \(melanogaster\)}, doi = {10.25972/OPUS-17879}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-178793}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2019}, abstract = {Since Channelrhodopsins has been described first and introduced successfully in freely moving animals (Nagel et al., 2003 and 2005), tremendous impact has been made in this interesting field of neuroscience. Subsequently, many different optogenetic tools have been described and used to address long-lasting scientific issues. Furthermore, beside the 'classical' Channelrhodopsin-2 (ChR2), basically a cation-selective ion channel, also altered ChR2 descendants, anion selective channels and light-sensitive metabotropic proteins have expanded the optogenetic toolbox. However, in spite of this variety of different tools most researches still pick Channelrhodopsin-2 for their optogenetic approaches due to its well-known kinetics. In this thesis, an improved Channelrhodopsin, Channelrhodopsin2-XXM (ChR2XXM), is described, which might become an useful tool to provide ambitious neuroscientific approaches by dint of its characteristics. Here, ChR2XXM was chosen to investigate the functional consequences of Drosophila larvae lacking latrophilin in their chordotonal organs. Finally, the functionality of GtACR, was checked at the Drosophila NMJ. For a in-depth characterisation, electrophysiology along with behavioural setups was employed. In detail, ChR2XXM was found to have a better cellular expression pattern, high spatiotemporal precision, substantial increased light sensitivity and improved affinity to its chromophore retinal, as compared to ChR2. Employing ChR2XXM, effects of latrophilin (dCIRL) on signal transmission in the chordotonal organ could be clarified with a minimum of side effects, e.g. possible heat response of the chordotonal organ, due to high light sensitivity. Moreover, optogenetic activation of the chordotonal organ, in vivo, led to behavioural changes. Additionally, GtACR1 was found to be effective to inhibit motoneuronal excitation but is accompanied by unexpected side effects. These results demonstrate that further improvement and research of optogenetic tools is highly valuable and required to enable researchers to choose the best fitting optogenetic tool to address their scientific questions.}, subject = {Optogenetik}, language = {en} } @article{RauschenbergerBehnkeGrotemeyeretal.2022, author = {Rauschenberger, Lisa and Behnke, Jennifer and Grotemeyer, Alexander and Knorr, Susanne and Volkmann, Jens and Ip, Chi Wang}, title = {Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease}, series = {Neurobiology of Disease}, volume = {171}, journal = {Neurobiology of Disease}, doi = {10.1016/j.nbd.2022.105798}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-300629}, year = {2022}, abstract = {The pathogenesis of Parkinson's disease (PD) is closely interwoven with the process of aging. Moreover, increasing evidence from human postmortem studies and from animal models for PD point towards inflammation as an additional factor in disease development. We here assessed the impact of aging and inflammation on dopaminergic neurodegeneration in the hm\(^{2}\)α-SYN-39 mouse model of PD that carries the human, A30P/A53T double-mutated α-synuclein gene. At 2-3 months of age, no significant differences were observed comparing dopaminergic neuron numbers of the substantia nigra (SN) pars compacta of hm\(^{2}\)α-SYN-39 mice with wildtype controls. At an age of 16-17 months, however, hm\(^{2}\)α-SYN-39 mice revealed a significant loss of dopaminergic SN neurons, of dopaminergic terminals in the striatum as well as a reduction of striatal dopamine levels compared to young, 2-3 months transgenic mice and compared to 16-17 months old wildtype littermates. A significant age-related correlation of infiltrating CD4+ and CD8\(^{+}\) T cell numbers with dopaminergic terminal loss of the striatum was found in hm\(^{2}\)α-SYN-39 mice, but not in wildtype controls. In the striatum of 16-17 months old wildtype mice a slightly elevated CD8\(^{+}\) T cell count and CD11b\(^{+}\) microglia cell count was observed compared to younger aged mice. Additional analyses of neuroinflammation in the nigrostriatal tract of wildtype mice did not yield any significant age-dependent changes of CD4\(^{+}\), CD8\(^{+}\) T cell and B220\(^{+}\) B cell numbers, respectively. In contrast, a significant age-dependent increase of CD8\(^{+}\) T cells, GFAP\(^{+}\) astrocytes as well as a pronounced increase of CD11b+ microglia numbers were observed in the SN of hm\(^{2}\)α-SYN-39 mice pointing towards a neuroinflammatory processes in this genetic mouse model for PD. The findings in the hm\(^{2}\)α-SYN-39 mouse model strengthen the evidence that T cell and glial cell responses are involved in the age-related neurodegeneration in PD. The slow and age-dependent progression of neurodegeneration and neuroinflammation in the hm\(^{2}\)α-SYN-39 PD rodent model underlines its translational value and makes it suitable for studying anti-inflammatory therapies.}, language = {en} } @article{GrotemeyerMcFlederWuetal.2022, author = {Grotemeyer, Alexander and McFleder, Rhonda Leah and Wu, Jingjing and Wischhusen, J{\"o}rg and Ip, Chi Wang}, title = {Neuroinflammation in Parkinson's disease - putative pathomechanisms and targets for disease-modification}, series = {Frontiers in Immunology}, volume = {13}, journal = {Frontiers in Immunology}, issn = {1664-3224}, doi = {10.3389/fimmu.2022.878771}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-274665}, year = {2022}, abstract = {Parkinson's disease (PD) is a progressive and debilitating chronic disease that affects more than six million people worldwide, with rising prevalence. The hallmarks of PD are motor deficits, the spreading of pathological α-synuclein clusters in the central nervous system, and neuroinflammatory processes. PD is treated symptomatically, as no causally-acting drug or procedure has been successfully established for clinical use. Various pathways contributing to dopaminergic neuron loss in PD have been investigated and described to interact with the innate and adaptive immune system. We discuss the possible contribution of interconnected pathways related to the immune response, focusing on the pathophysiology and neurodegeneration of PD. In addition, we provide an overview of clinical trials targeting neuroinflammation in PD.}, language = {en} }